Saphenous Neuromodulation

Unlocking a New Era of Therapeutic
Possibilities for Patients and Physicians

A New, Disruptive Approach to Treating OAB

Noninvasive Saphenous
Neuromodulation (nSAFN)

Discovered and patented1 at the University of Toronto by EBT’s co-founder Professor Paul Yoo, saphenous neuromodulation presents totally new possibilities for treating overactive bladder.

Saphenous neuromodulation (SAFN) works via a centralized mechanism, making it ideal for intermittent stimulation rather than continuous. This novel target offers numerous advantages over existing neuromodulation targets, including the tibial nerve.

Key Saphenous Nerve Characteristics

Shallow Subcutaneous / Suprafascial Location

Allows for targeted noninvasive nerve stimulation

Upper Calf Location

Easy to reach for patient

Lower Bladder Inhibition Level

83%2 lower bladder inhibition threshold vs. other targets3 allowing for less energy to deliver therapy

Afferent (Sensory) Only Nerve

More comfortable treatment experience and not limited by motor nerve side-effects

nSAFN has been studied in multiple feasibility studies in the US and Canada for OAB and other indications, with results3 equally effective or better than published results for existing invasive therapies and medications.

OAB sufferers, who number roughly 550M worldwide, have the opportunity to experience treatment without the significant side-effects that come with drugs, or the invasiveness and side-effects that come with botulinum toxin or traditional approaches to neuromodulation.

Press Play to Learn About the Mechanism of Action for nSAFN for OAB

Learn About the Mechanism of Action for nSAFN for OAB

Data from three feasibility studies3 points to OAB symptom responder rates that are better than third-line therapies, with no surgery, and only mild transient side-effects

19,610,442. 9,884,187

2Moazzam, Z. & Yoo, P. (2018). Frequency-dependent inhibition of bladder function by saphenous nerve stimulation in anesthetized rats. Neurourology and urodynamics37(2), 592–599.

3Feasibility clinical outcomes, data on file.